January 24, 2002Open Access
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Key Points
Key points are not available for this paper at this time.
Abstract
The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Coiffier et al. (Thu,) studied this question.
synapsesocial.com/papers/69d9af2b387cf7069868519e — DOI: https://doi.org/10.1056/nejmoa011795
Authors
Bertrand Coiffier
Université Claude Bernard Lyon 1
É
Éric Lepage
Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean
J
Josette Brière
Délégation Paris 7
Journals
New England Journal of Medicine
Actions
Institutions
Assistance Publique – Hôpitaux de Paris
Université Claude Bernard Lyon 1
Hôpital Saint-Louis
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...